Abstract
In this Correspondence, A. Sharma & C. Wolfrum report that DGAT1/2 pharmacological inhibition at post-absorptive phase in mice leads to increased fatty acid oxidation and reduced plasma fatty acid levels, which could open new therapeutic avenues to avoid GI complications observed in clinical trials.